Effect of early different-dose simvastatin therapy on the serum C-reactive protein, fibrin degradation product and D-dimer in the patients with acute coronary syndrome
AIM: To evaluate the effect of early different-dose simvastatin therapy on the serum C-reactive protein (CRP), fibrin degradation product (FDP) and D-dimer in the patients with acute coronary syndrome (ACS), except the change of the blood-lipid. METHODS: Ninety patients with ACS were divided into 3 groups. The patients in group 1 (n = 30) received simvastatin (20 mg/d). The patients in group 2(n = 30) received simvastatin (10 mg/d) and the group 3 was the control group (n = 30). The patients in group 1 and in group 2 were treated with simvastatin within 24-48 h after hospitalization. The levels of the high sensitivity CRP(hs-CRP), FDP, D-dimer and the blood-lipid were measured at baseline and after 8 weeks of therapy. RESULTS: After 8 weeks of therapy, early different-dose simvastatin treatmemt can not only decrease the serum level of blood-lipid, but also decrease the serum level of hs-CRP, FDP and D-dimer. The higher dose, the more effect. CONCLUSION: Early simvastatin treatmemt can inhibit inflammtion and blood coagulative reation obviously. As the dose is higher,the effect is more obvious.
NETL
NSTL
万方数据
维普
